BIOLASE, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Concentrations

Concentrations

6 Months Ended

Jun. 30, 2018

NOTE 12—CONCENTRATIONS

Revenue from the Company’s products for the three and six months ended June 30, 2018 and 2017 are as follows (dollars in thousands):

	Three Months Ended								Six Months Ended
	June 30,								June 30,
	2018				2017				2018				2017
Laser systems	$	7,920	65.2	%	$	7,961	63.1	%	$	13,623	61.4	%	$	14,690	62.6	%
Imaging systems		371	3.1	%		954	7.5	%		954	4.3	%		1,580	6.7	%
Consumables and other		2,303	18.9	%		2,051	16.3	%		4,337	19.6	%		3,743	15.9	%
Services		1,557	12.8	%		1,614	12.8	%		3,254	14.7	%		3,409	14.5	%
License fees and royalties		3	0.0	%		32	0.3	%		6	0.0	%		64	0.3	%
Total revenue	$	12,154	100.0	%	$	12,612	100.0	%	$	22,174	100.0	%	$	23,486	100.0	%

No individual customer represented more than 10% of the Company’s revenue for the three and six months ended June 30, 2018 or 2017.

The Company maintains its cash and cash equivalent accounts with established commercial banks. Such cash deposits periodically exceed the Federal Deposit Insurance Corporation insured limit.

No individual customer represented more than 10% of the Company’s accounts receivable at June 30, 2018 or December 31, 2017.

The Company currently purchases certain key components of its products from single suppliers. Although there are a limited number of manufacturers of these key components, management believes that other suppliers could provide similar key components on comparable terms. A change in suppliers, however, could cause delays in manufacturing and a possible loss of sales, which could adversely affect the Company’s business, results of operations and financial condition.